Drugs / PLL001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06513546 | Apr → Dec 2026 expected | amyotrophic lateral sclerosis | PLL TX AUSTRALIA PTY LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLL001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06513546 ↗ |
| Modality | Other / unclassified | “PLL001 consists of the combination of 4 drug substances (DS)” NCT06513546 ↗ |
| Route | Subcutaneous | “daily subcutaneous injections” NCT06513546 ↗ |